Search
Amrinone
go.drugbank.com/drugs/DB01427ApprovedWithdrawnAmrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.
S-40503
go.drugbank.com/drugs/DB13938ExperimentalS-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.
AAV-dXIAP
go.drugbank.com/drugs/DB17880ExperimentalAAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.
Alintegimod
go.drugbank.com/drugs/DB18879InvestigationalAlintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).
Oxyquinoline
go.drugbank.com/drugs/DB11145ApprovedInvestigationalVet approvedOxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalLenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.
Ticarcillin
go.drugbank.com/drugs/DB01607ApprovedVet approvedWithdrawnAn antibiotic derived from penicillin similar to carbenicillin in action.
KW-7158
go.drugbank.com/drugs/DB05498ExperimentalKW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity … The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion
BB-301
go.drugbank.com/drugs/DB17011Investigational[A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).[L47062] … BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small
LU-31130
go.drugbank.com/drugs/DB05828ExperimentalLU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.